Neugenesis’ fungal expression technology will be incorporated into Sepragen’s solid-phase bioreactor.

Sepragen and Neugenesis are collaborate to develop a high-throughput, low-cost production platform for mAbs and vaccines for pandemic flu. Neugenesis will grow its Neurospora expression system in Sepragen’s solid-phase bioreactor.

“Neurospora expression systems enable faster production of recombinant proteins than mammalian cells, and Sepragen’s bioreactor enables rapid multifold growth of a variety of cells without limitations of oxygen inhibition, the firms point out.

The project is funded in part by a DARPA contract to Neugenesis under the Accelerated Manufacturing Process (AMP) project.

Previous articleArtes Biotechnology Produces Virus-Like Particles for Select Vaccines from a Yeast-Based System
Next articleBaylor and 454 Publish Sequence and Analysis of James Watson’s Genome